These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6932389)

  • 21. H-2-specific antibodies induced by injection of syngeneic leukemia cells.
    Schmidt W
    Immunogenetics; 1987; 25(4):215-21. PubMed ID: 3570375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD4-CD8+ T lymphocytes mediate AKR/gross murine leukemia virus nonresponsiveness in moderately aged AKR.H-2b:Fv-1b mice.
    Rich RF; Fujii T; Green WR
    J Immunol; 1992 May; 148(9):2961-7. PubMed ID: 1349325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A simple and convenient method for producing anti-activated lymphocyte alloantisera which does not require prior absorption.
    Kerbel RS; Twiddy RR
    J Immunol Methods; 1978; 21(1-2):11-22. PubMed ID: 659895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specificity of cytolytic T cells directed against AKR/Gross virus-induced syngeneic leukemias: antibodies directed against H-2K, but not against viral proteins, inhibit lysis.
    Green WR; Nowinski RC; Henney CS
    J Immunol; 1980 Aug; 125(2):647-55. PubMed ID: 6156211
    [No Abstract]   [Full Text] [Related]  

  • 25. Induction of gp70-specific suppressor T-cells in mice inoculated with virus-producing tumor cells.
    Bluestone JA; Lopez C
    J Natl Cancer Inst; 1982 Oct; 69(4):953-9. PubMed ID: 6214655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ly-15: a new murine lymphocyte alloantigenic locus.
    Potter TA; Hogarth PM; McKenzie IF
    Transplantation; 1981 May; 31(5):339-42. PubMed ID: 6785912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The generation and specificity of cytotoxic T cells raised against syngeneic tumor cells bearing AKR/Gross murine leukemia virus antigens.
    Green WR; Nowinski RC; Henney CS
    J Exp Med; 1979 Jul; 150(1):51-66. PubMed ID: 109575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The immune response of (C57BL/6 X C3H)F1 mice to the endogenous AKR-MuLV.
    Ihle JN; Lee JC
    Med Microbiol Immunol; 1977; 164(1-3):207-16. PubMed ID: 202851
    [No Abstract]   [Full Text] [Related]  

  • 29. Impaired generation of anti-AKR/Gross murine leukemia virus cytotoxic T lymphocytes in mice experimentally infected with MuLV.
    Coppola MA; Green WR; Rich RF
    Viral Immunol; 1996; 9(2):107-19. PubMed ID: 8822627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic control of the induction of cytolytic T lymphocyte responses to AKR/Gross viral leukemias. I. H-2-encoded dominant gene control.
    Green WR
    J Immunol; 1984 May; 132(5):2658-64. PubMed ID: 6425409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrovirus antigens recognized by cytolytic T lymphocytes activate tumor rejection in vivo.
    Plata F; Langlade-Demoyen P; Abastado JP; Berbar T; Kourilsky P
    Cell; 1987 Jan; 48(2):231-40. PubMed ID: 3026637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autogenous immunity to endogenous RNA tumor virus: reactivity of natural immune sera to antigenic determinants of several biologically distinct murine leukemia viruses.
    Lee JC; Ihle JN
    J Natl Cancer Inst; 1975 Oct; 55(4):831-8. PubMed ID: 52718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a viral antigen recognized by H-2-restricted cytolytic T lymphocytes on a murine leukemia virus-induced tumor.
    Plata F; Kalil J; Zilber MT; Fellous M; Lévy D
    J Immunol; 1983 Nov; 131(5):2551-6. PubMed ID: 6605389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liposomes as a tool to study the role of membrane presentation in the immunogenicity of a MuLV-related tumor antigen.
    Gerlier D; Bakouche O; Dore JF
    J Immunol; 1983 Jul; 131(1):485-90. PubMed ID: 6190925
    [No Abstract]   [Full Text] [Related]  

  • 35. Anomalous reactions of mouse alloantisera with cultured tumor cells. II. Cytotoxicity is caused by antibodies to leukemia viruses.
    Nowinski RC; Klein PA
    J Immunol; 1975 Nov; 115(5):1261-8. PubMed ID: 170342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymphoma development from transplanted murine leukemia virus infected organ cultured thymuses: inhibitory effect of in vitro interferon treatment.
    Riesenfeld I; Tufveson G; Alm GV
    Int J Cancer; 1980 Apr; 25(4):529-34. PubMed ID: 6154660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virion and non-virion murine leukemia membrane antigens: analysis with virus-absorbed antisera.
    Moroni C; Robert-Guroff M; Martin D
    Intervirology; 1974; 3(5-6):292-304. PubMed ID: 4443190
    [No Abstract]   [Full Text] [Related]  

  • 38. AKR leukemia-specific surface antigens acquired by malignant transformation: their common and individual specificities.
    Okazaki E; Aoki T; De Kozlowski SJ
    Int J Cancer; 1976 May; 17(5):640-6. PubMed ID: 57936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of leukemogenesis. I. Generation of autoreactive lymphocytes in response to a murine leukemia virus.
    Schenk PJ; Howe ML
    J Immunol; 1979 May; 122(5):1874-80. PubMed ID: 221580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Redistribution and modulation of Gross murine leukemia virus antigens induced by specific antibodies.
    Ioachim HL; Sabbath M
    J Natl Cancer Inst; 1979 Jan; 62(1):169-80. PubMed ID: 281570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.